COEP Key Statistics, Chart & Performance
The current stock price of COEP is 13.86 USD. In the past month the price decreased by -2.74%. In the past year, price increased by 7.03%.
COEP Technical Analysis
COEP Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
COEP Forecast & Estimates
COEP Ownership
About COEP
Company Profile
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Company Info
COEPTIS THERAPEUTICS HOLDING
105 Bradford Road, Suite 420
Wexford PENNSYLVANIA US
Employees: 5
Phone: 17249346467
COEPTIS THERAPEUTICS HOLDING / COEP FAQ
What does COEPTIS THERAPEUTICS HOLDING do?
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
What is the stock price of COEPTIS THERAPEUTICS HOLDING today?
The current stock price of COEP is 13.86 USD. The price increased by 1.84% in the last trading session.
Does COEP stock pay dividends?
COEP does not pay a dividend.
How is the ChartMill rating for COEPTIS THERAPEUTICS HOLDING?
COEP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the next earnings date for COEP stock?
COEPTIS THERAPEUTICS HOLDING (COEP) will report earnings on 2026-03-25, after the market close.
What is the outstanding short interest for COEPTIS THERAPEUTICS HOLDING?
The outstanding short interest for COEPTIS THERAPEUTICS HOLDING (COEP) is 7.69% of its float.